A Review of Fixed-Dose Combination Therapy for Secondary Prevention of Adverse Cardiovascular Events and the Preliminary Results of the Persianpolypill Randomized Clinical Trial

Document Type : Review Article

Authors

1 Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 MD, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3 Pharmacist, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran

4 Professor, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

5 Professor, Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

6 Associate Professor, Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

7 Assistant Professor, Department of Physical Medicine and Rehabilitation, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v42.i771.0499

Abstract

Background: This article is an update on our previous review of clinical studies on the role of polypills in the secondary prevention of cardiovascular diseases (CVD). We also present the preliminary results of the Persian Polypill study.
Methods: Persian Polypill is a randomized clinical trial with two parallel arms on hospitalized patients due to acute myocardial infarction (AMI). It is planned that 1100 patients will be randomly assigned to one of the two arms of Polypill or usual care and will be followed up for 34 months. The primary outcome will be a composite clinical outcome of major adverse cardiovascular events (MACE), and the secondary outcome will be the cost-effectiveness of polypill treatment.
Findings: We identified ten completed studies and two ongoing trials in which at least 10% of participants had CVD. The evaluation of these studies showed the lack of research in low- and middle-income countries about the role of polypill in secondary prevention of CVD and limited information about cost-effectiveness resulting from clinical trials. In Persian Polypill, so far, 624 patients admitted to three hospitals due to AMI have been included in the study. The average age of patients is 60.9 ± 8.7 and 506 are male (81.1%). Overall, 94.4% of the patients underwent percutaneous coronary intervention in the hospital, and 26.3% had hospital complications.
Conclusion: The final results of this study can compensate for the gap in the past studies. They may confirm the role of polypill in the initial management of AMI and long-term secondary prevention in these patients.

Highlights

Masoumeh Sadeghi: Google Scholar

Shervin Ghaffari Hoseini: Google Scholar

Keywords

Main Subjects

References

  1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017; 135(10): e146-e603.
  2. Mensah GA, Fuster V, Murray CJL, Roth GA. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. J Am Coll Cardiol 2023; 82(25): 2350-473.
  3. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2023; 148(9): e9-e119.
  4. Mahmoudi Kohi S, Mohammadifard N, Hassannejad R, Nouri F, Mansourian M, Sarrafzadegan N. Explaining the decline in coronary heart disease mortality rate using IMPACT Model: Estimation of the Changes in Risk Factors and Treatment Uptake in Iran between 2007 and 2016. ARYA Atheroscler 2023; 19(3): 33-42.
  5. Liu Z, Yan M, Tse LA, Zhu Y, Lang X, Liu X, et al. Achievement of Guideline-Recommended Targets for Secondary Prevention of Cardiovascular Disease in 38 Low-Income and Middle-Income Countries. J Epidemiol Glob Health 2024.
  6. Widyakusuma NN, Suryawati S, Wiedyaningsih C, Probosuseno. What Do Seniors Believe About Medication Adherence? A Qualitative Study Among Seniors with Chronic Conditions in Yogyakarta, Indonesia. Patient Prefer Adherence 2023; 17: 1381-92.
  7. Huffman MD, Xavier D, Perel P. Uses of polypills for cardiovascular disease and evidence to date. Lancet 2017; 389(10073): 1055-65.
  8. Bahiru E, de Cates AN, Farr MR, Jarvis MC, Palla M, Rees K, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev 2017; 3(3): Cd009868.
  9. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310(9): 918-29.
  10. Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014; 348: g3318.
  11. Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015; 22(7): 920-30.
  12. Castellano JM, Sanz G, Penalvo JL, Bansilal S, Fernandez-Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 2014; 64(20): 2071-82.
  13. Mariani J, Rosende A, De Abreu M, Gonzalez Villa Monte G, D'Imperio H, Antonietti L, et al. Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial. Ther Adv Cardiovasc Dis 2020; 14: 1753944720912071.
  14. Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 2019; 394(10199): 672-83.
  15. González-Juanatey JR, Cordero A, Castellano JM, Masana L, Dalmau R, Ruiz E, et al. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study. Int J Cardiol 2022; 361: 116-23.
  16. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022; 387(11): 967-77.
  17. Ansbro É, Masri S, Prieto-Merino D, Willis R, Aoun Bahous S, Molfino L, et al. Fixed dose combination drugs for cardiovascular disease in a prolonged humanitarian crisis in Lebanon: an implementation study. BMJ Open 2023; 13(1): e063668.
  18. Malekzadeh F, Gandomkar A, Poustchi H, Etemadi A, Roshandel G, Attar A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular disease: a pragmatic cluster-randomised controlled trial (PolyPars). Heart 2024; 110(14): 940-6.
  19. Selak V, Webster R, Stepien S, Bullen C, Patel A, Thom S, et al. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart 2019; 105(1): 42-8.
  20. Malekzadeh F, Gandomkar A, Malekzadeh Z, Poustchi H, Moghadami M, Fattahi MR, et al. Effectiveness of polypill for prevention of cardiovascular disease (PolyPars): protocol of a randomized controlled trial. Arch Iran Med 2020; 23(8): 548-56.
  21. Agarwal A, Mehta PM, Jacobson T, Shah NS, Ye J, Zhu J, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease. Nat Med 2024; 30(4): 1199-209.
  22. Hayek A, Joshi R, Usherwood T, Webster R, Kaur B, Saini B, et al. An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial. Implement Sci 2016; 11(1): 129.
  23. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-81.
  24. Lafeber M, Spiering W, Visseren FL, Grobbee DE, Bots ML, Stanton A, et al. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Eur J Prev Cardiol 2017; 24(9): 951-61.
  25. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378(9798): 1231-43.
  26. Barrios V, Kaskens L, Castellano JM, Cosin-Sales J, Ruiz JE, Zsolt I, et al. Usefulness of a cardiovascular polypill in the treatment of secondary prevention patients in spain: a cost-effectiveness study. Rev Esp Cardiol (Engl Ed) 2017; 70(1): 42-9.
  27. Gaziano TA, Pandya A, Sy S, Jardim TV, Ogden JM, Rodgers A, et al. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J 2019; 214: 77-87.
  28. Lin JK, Moran AE, Bibbins-Domingo K, Falase B, Pedroza Tobias A, Mandke CN, et al. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study. Lancet Glob Health 2019; 7(10): e1346-e58.
  29. Sadeghi M, Hoseini SG, Nateghi A, Sarrafzadegan N, Mansoorian M, Najafian J, et al. Fixed dose combination therapy for secondary prevention of major cardiovascular events: review of literature and design for Persian Polypill, a randomized clinical trial. Curr Probl Cardiol 2022; 47(6): 100872.
  30. Montazeri A, Vahdaninia M, Mousavi SJ, Omidvari SJBph. The Iranian version of 12-item Short Form Health Survey (SF-12): factor structure, internal consistency and construct validity. BMC Public Health 2009; 9: 341.
  31. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, et al. Effect of intensive blood-pressure treatment on patient-reported outcomes. N Engl J Med 2017; 377(8): 733-44.
  32. Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, et al. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2017; 377(8): 745-55.
  33. Mendez-Garcia LA, Gonzalez-Chavez A, Trejo-Millan F, Navarrete-Zarco HU, Carrero-Aguirre M, Melendez G, et al. Six month Polypill therapy improves lipid profile in patients with previous acute myocardial infarction: the heart-mex study. Arch Med Res 2019; 50(4): 197-206.
  34. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013; 158(3):
    200-7.
Journal of Isfahan Medical School
Volume 42, Issue 771
3rd Week, August
July and August 2024
Pages 499-512

Files

History

  • Receive Date: 05 June 2024
  • Accept Date: 07 September 2024

Share

How to cite

Statistics